<DOC>
	<DOCNO>NCT02131662</DOCNO>
	<brief_summary>The study perform assess efficacy safety different dos BAY1002670 subject uterine fibroid . The dose-response relationship evaluate . Further , study aim establish population pharmacokinetic/pharmacodynamic relationship BAY1002670 subject uterine fibroid . To assess efficacy BAY1002670 interchangeability menstrual pictogram alkaline hematin method judgement menstrual blood loss assess .</brief_summary>
	<brief_title>Bay1002670 , Fibroids , Safety Efficacy EU , US , Can , Jap</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<criteria>Signed date informed consent Diagnosis uterine fibroid ( ) document transvaginal abdominal ultrasound screen least 1 fibroid large diameter 3.0 cm 18 50 year age time screen Heavy menstrual bleeding &gt; 80 mL document MP bleed episode follow screen visit Normal clinically insignificant cervical smear require followup An endometrial biopsy perform screen visit 1 ( Visit 1 ) , without significant histological disorder endometrial hyperplasia significant endometrial pathology Use nonhormonal barrier method contraception start bleed episode follow screen visit 1 ( Visit 1 ) end study Good general health ( except finding relate uterine fibroid ) Pregnancy lactation Uterine fibroid large diameter &gt; 10.0 cm Hypersensitivity ingredient study drug Laboratory value outside inclusion range randomization consider clinically relevant Hemoglobin value &lt; 6 g/dL condition require immediate blood transfusion ( subject hemoglobin value &lt; 10.9 g/dL receive iron supplementation ) Any disease condition compromise function body system could result altered absorption , excessive accumulation , impaired metabolism , alter excretion study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Uterine fibroid</keyword>
</DOC>